Form 4: Intuitive Surgical SVP Mark Brosius Executes Stock Sales Under 10b5-1 Trading Plan

Mark Brosius, SVP & Chief Manufacturing and Supply Chain Officer at Intuitive Surgical, sold a total of 525 shares of common stock between May 13 and May 15, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Mark Brosius, a Senior Vice President at Intuitive Surgical, sold shares of the company's common stock.
• The sales occurred on May 13, 14, and 15 of 2024.
• A total of 525 shares were sold across the three days.
• The sales were executed under a pre-arranged trading plan that complies with SEC Rule 10b5-1.
• The trading plan is set to expire on June 7, 2024.
• The prices per share ranged from $380.85 to $389.16.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-existing trading plan, which is a routine activity.

Industry Context

Executive stock sales are a common occurrence, and sales under 10b5-1 plans are generally viewed as less impactful since they are pre-arranged. However, investors often monitor these transactions for insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Executive compensation and stock sales are common across the medical device industry.
• Companies like Stryker (SYK), Medtronic (MDT), and Johnson & Johnson (JNJ) also see regular Form 4 filings from their executives.
• The size and frequency of these sales are often benchmarked against industry peers to assess if they are within the norm or indicative of specific company-related factors.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if they interpret the sales negatively, although sales under 10b5-1 plans are generally viewed as less significant.
• The impact on employees, customers, suppliers, and creditors is expected to be minimal.

Key Dates